The Impact of COVID-19 on the Pharma Industry and Recent Developments Involving Biosimilars and Generics
Presented by the CBA Competition Law Section
CBA members: $55
CBA Young Lawyer Members (<5 years): $40
CBA Student members: $10
Non-members: $220
Plus applicable taxes
Registrants will receive an on-demand recording following each webcast. All sessions will be presented in English.
This is the 5th webinar in the CBA Competition Law Fall Online Symposium. You can purchase the full program at a package rate.
WEDNESDAY, OCTOBER 21, 12:30 PM TO 1:45 PM ET
12:30 pm – 1:45 pm The Impact of COVID-19 on the Pharma Industry and Recent Developments Involving Biosimilars and Generics
Sponsored by
This panel will discuss how competition laws might impact the development and distribution of COVID-19 vaccines and medicines, and related competitor collaboration. Our experts will also explore novel issues raised by biosimilars, including in the context of class actions and the recently published joint statement from the FTC and the FDA, and access of branded samples to generic manufacturers following the Otsuka investigation.
Moderator:
Davit Akman, Borden Ladner Gervais LLP
Speakers:
Eric Grannon, White & Case LLP
Eric Lefebvre, Norton Rose Fulbright LLP
Krista McWhinnie, Deputy Commissioner, Monopolistic Practices Directorate, Competition Bureau
Markus Meier, Assistant Director, Bureau of Competition, Federal Trade Commission
The webinar will include a Q&A portion
